Direct‐acting antivirals for chronic hepatitis C

. 2017 Jun 6;2017(6):CD012143. doi: 10.1002/14651858.CD012143.pub2

Database	Time span	Search strategy
The Cochrane Hepato‐Biliary Group Controlled Trials Register	28 October 2016	directacting antiviral or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS*790052 and (chronic and (hepatitis C or hep C or HCV))
Cochrane Central Register of Controlled Trials (Wiley)	2016, Issue 9	#1 MeSH descriptor: [Antiviral Agents] explode all trees #2 MeSH descriptor: [Protease Inhibitors] explode all trees #3 MeSH descriptor: [Nucleic Acid Synthesis Inhibitors] explode all trees #4 directacting antiviral or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS*790052 #5 #1 or #2 or #3 or #4 #6 MeSH descriptor: [Hepatitis C, Chronic] explode all trees #7 chronic and (hepatitis C or hep C or HCV) #8 #6 or #7 #9 #5 and #8
MEDLINE (OvidSP)	1946 to 28 October 2016	1. exp Antiviral Agents/ 2. exp Protease Inhibitors/ 3. exp Nucleic Acid Synthesis Inhibitors/ 4. (directacting antiviral or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS790052).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 5. 1 or 2 or 3 or 4 6. exp Hepatitis C, Chronic/ 7. (chronic and (hepatitis C or hep C or HCV)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 8. 6 or 7 9. 5 and 8 10. (random or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 11. 9 and 10
Embase (Ovid SP)	1974 to 28 October 2016	1. exp antivirus agent/ 2. exp proteinase inhibitor/ 3. exp nucleic acid synthesis inhibitor/ 4. (directacting antiviral or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS790052).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 5. 1 or 2 or 3 or 4 6. exp chronic hepatitis C/ 7. (chronic and (hepatitis C or hep C or HCV)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 8. 6 or 7 9. 5 and 8 10. (random or blind* or placebo* or meta‐analys*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 11. 9 and 10
Science Citation Index Expanded (Web of Science)	1900 to 28 October 2016	#5 #4 AND #3 #4 TS=(random* or blind* or placebo* or meta‐analys) #3 #2 AND #1 #2 TS=(chronic and (hepatitis C or hep C or HCV)) #1 TS=(directacting antiviral* or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS*790052)
LILACS (Bireme)	1982 to 28 October 2016	(chronic and (hepatitis C or hep C or HCV)) [Words] and ((antiviral$ or DAA$ or ((protease or polymerase) and inhibitor$)) or (telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira$ or technivie or NPI$ or harvoni or daklinza or sovaldi or exviera or USAN$ or VX$135 or VX$222 or VX$950 or ABT$072 or ABT$450 or TMC$647055 or TMC$435 or GSK$2336805 or GS$9256 or GS$5885 or PPI$461 or BI$201127 or INX$189 or BMS$986094 or BMS$790052)) [Words]
BIOSIS (Web of Science)	1969 to 28 October 2016	#5 #4 AND #3 #4 TS=(random* or blind* or placebo* or meta‐analys) #3 #2 AND #1 #2 TS=(chronic and (hepatitis C or hep C or HCV)) #1 TS=(directacting antiviral* or DAA* or ((protease or polymerase) and inhibitor) or telaprevir or boceprevir or simeprevir or paritaprevir or faldaprevir or asunaprevir or grazoprevir or sovaprevir or danoprevir or vedroprevir or vaniprevir or narlaprevir or sofosbuvir or dasabuvir or beclabuvir or deleobuvir or filibuvir or setrobuvir or radalbuvir or tegobuvir or ledipasvir or ombitasvir or declatasvir or elbasvir or odalasvir or samatasvir or ravidasvir or mericitabine or incivek or incivo or telavic or sunpreva or victrelis or INN or olysio or sovriad or galexos or viekira or technivie or NPI* or harvoni or daklinza or sovaldi or exviera or USAN* or VX135 or VX222 or VX950 or ABT072 or ABT450 or TMC647055 or TMC435 or GSK2336805 or GS9256 or GS5885 or PPI461 or BI201127 or INX189 or BMS986094 or BMS*790052)